Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03263351 · ClinicalTrials.gov registry record · NA

Depression & Insulin Sensitivity in Adolescents

A NA study, sponsored by Colorado State University.

Completed
Registry status
NA
Development phase
147
Enrollment target

NCT03263351: Completed NA study, sponsored by Colorado State University.

NCT03263351 is a NA study that has completed, run by Colorado State University. The registered enrollment target is 147 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03263351, a NA study, has completed, sponsored by Colorado State University.

COMPLETED
Registry status
NA
Development phase
147 participants
Enrollment target

Study Summary

There has been a rise in type 2 diabetes (T2D) rates in adolescents, disproportionately in girls from disadvantaged racial/ethnic groups. This group of girls also is at heightened risk for depression, and depression and T2D are linked. Depressive symptoms are a risk factor for worsening of insulin sensitivity, one if the major precursors to T2D. In preliminary studies, the investigators found that a brief cognitive-behavioral therapy group decreased depressive symptoms and prevented worsening of insulin sensitivity in adolescent girls at-risk for T2D with moderate depressive symptoms. The aims of this study are: 1) to assess the efficacy of a cognitive-behavioral therapy depression group vs. a health education control group for improving insulin sensitivity and preserving insulin secretion in racially/ethnically diverse adolescent girls at-risk for T2D with moderate depressive symptoms over a 1-year follow-up; 2) to evaluate changes in eating, physical activity, and sleep as explanatory and 3) to test changes in cortisol factors as explanatory.

Primary Outcome

Center for Epidemiologic Studies-Depression Scale (CES-D) total score

Interventions

  • BEHAVIORAL Cognitive-behavioral therapy group
  • BEHAVIORAL Health education group

Trial Details

FieldValue
Enrollment Target 147 participants
Start Date 2017-10-01
Est. Completion 2025-05-26
Phase NA
Colorado State University

94 total trials

What the finished NCT03263351 record still lists

NCT03263351 is an interventional study that assigns participants to a tested intervention. The registered 147 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (90% lower).

The record links to 0 conditions, and to 2 interventions - of which Cognitive-behavioral therapy group is the first listed.

NCT03263351 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03263351 about?

NCT03263351 is a clinical study titled "Depression & Insulin Sensitivity in Adolescents". There has been a rise in type 2 diabetes (T2D) rates in adolescents, disproportionately in girls from disadvantaged racial/ethnic groups. This group of girls also is at heightened risk for depression, and depression and T2D are linked. Depressive symptoms are a risk factor for worsening of insulin s...

What is the current status of trial NCT03263351?

This trial is currently completed. It is a NA study. The enrollment target is 147 participants. The study started on 2017-10-01. Estimated completion is 2025-05-26.

What interventions are being tested in trial NCT03263351?

The interventions under investigation include: Cognitive-behavioral therapy group (BEHAVIORAL), Health education group (BEHAVIORAL).

Who is sponsoring clinical trial NCT03263351?

This trial is sponsored by Colorado State University, which has 94 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03263351's enrollment target sits among peer trials

147 703rd of 2000 higher than 1,297 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04396613 · 147 participants · NA

    Wound Closure Techniques in Primary Spine Surgery

  • NCT04851119 · 147 participants · Phase 1

    Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • NCT05523947 · 147 participants · Phase 1

    Clinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor

  • NCT06121843 · 147 participants · Phase 1

    A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03263351, the US trial registry maintained by the National Library of Medicine. NCT03263351 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.